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ABSTRACT
Pancreatic ductal adenocarcinomas (PDACs) overexpress pro-angiogenic 
factors but are not viewed as vascular. Using data from The Cancer Genome Atlas 
we demonstrate that a subset of PDACs exhibits a strong pro-angiogenic signature 
that includes 37 genes, such as HDAC9, that are overexpressed in PDAC arising 
in KRC mice, which express mutated Kras and lack RB. Moreover, patient-derived 
orthotopic xenografts can exhibit tumor angiogenesis, whereas conditioned media 
(CM) from KRC-derived pancreatic cancer cells (PCCs) enhance endothelial cell (EC) 
growth and migration, and activate canonical TGF-β signaling and STAT3. Inhibition 
of the type I TGF-β receptor with SB505124 does not alter endothelial activation in 
vitro, but decreases pro-angiogenic gene expression and suppresses angiogenesis 
in vivo. Conversely, STAT3 silencing or JAK1–2 inhibition with ruxolitinib blocks CM-
enhanced EC proliferation. STAT3 disruption also suppresses endothelial HDAC9 and 
blocks CM-induced HDAC9 expression, whereas HDAC9 re-expression restores CM-
enhanced endothelial proliferation. Moreover, ruxolitinib blocks mitogenic EC/PCC 
cross-talk, and suppresses endothelial p-STAT3 and HDAC9, and PDAC progression 
and angiogenesis in vivo, while markedly prolonging survival of KRC mice. Thus, 
targeting JAK1–2 with ruxolitinib blocks a final pathway that is common to multiple 
pro-angiogenic factors, suppresses EC-mediated PCC proliferation, and may be useful 
in PDACs with a strong pro-angiogenic signature.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer-related deaths in the United 
States, with dismal overall 5-year survival rates of 6% 
[1]. PDAC most often presents at an advanced stage and 
with metastatic disease, which precludes resection, and 
is often associated with marked chemoresistance and 
intense desmoplasia that may interfere with tumor blood 
flow and hinder drug penetration into the pancreatic tumor 
mass [2–5]. Nonetheless, PDAC often exhibits foci of 
endothelial cell (EC) proliferation, and several [6–8], but 
not all [9] studies, have reported a positive correlation 
between blood vessel density, tumor vascular endothelial 
growth factor-A (VEGF-A) levels, and disease progression 
in PDAC. Moreover, pancreatic cancer cell lines secrete 
biologically active VEGF-A [10], and its expression in 
the pancreatic cancer cells (PCCs) may be associated with 
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enhanced local tumor spread, increased incidence of liver 
metastasis, and decreased patient survival [6–8].
Studies using subcutaneous and orthotopic mouse 
models of PDAC have suggested that anti-angiogenic 
therapy is effective at suppressing pancreatic tumor 
growth. Thus, the anti-angiogenic agent TNP-470 reduced 
neoangiogenesis in tumors formed by MIA-PaCa-2, 
ASPC-1, and CAPAN-1 PCCs, resulting in decreased 
tumor growth and metastatic spread [11]; targeting 
VEGF-A expression with a VEGF antisense construct 
markedly attenuated tumorigenicity in nude mice [10]; 
VEGF-A fused to diphtheria toxin (DT-VEGF) internalizes 
in target cells via VEGFRs, inhibits protein synthesis, and 
directly suppresses the growth of HUVEC ECs, while 
decreasing tumor volume, tumor spread, and microvessel 
density in tumors formed by HPAF-2 and ASPC-1 PCCs 
[12]; adenoviral vectors carrying sequences encoding 
soluble VEGFR-1 and VEGFR-2 [13, 14], or the VEGFR 
tyrosine kinase inhibitor PTK 787 [15], inhibit the growth 
and metastasis of pancreatic tumors in severe combined 
immune deficient (SCID) mice and athymic mice.
Studies with the KPC genetically engineered mouse 
model (GEMM) of PDAC, which expresses mutated Kras 
and p53 alleles in the pancreas due to Pdx1-driven Cre 
recombination [16], have suggested that pancreatic tumor 
masses have a paucity of blood flow [17–19] that can be 
enhanced to facilitate drug delivery to the tumor mass 
using therapies that promote tumor angiogenesis [19], 
or by targeting the stroma [17, 18]. However, a separate 
GEMM-based study using KPfl/+C mice, which also 
express mutated Kras but have p53 haploinsufficiency, 
suggested that stroma depletion worsens disease, but that it 
is reversible by anti-angiogenesis therapy with a VEGFR2 
blocking antibody [20, 21]. Thus, whether angiogenesis 
should be targeted in PDAC is not entirely clear.
Although studies in certain murine models raise 
the possibility that VEGFR signaling may have an 
important role in PDAC, targeting VEGF-A either with 
bevacizumab, an anti-VEGF-A antibody, or with VEGF 
Trap, which sequesters VEGF, has failed in clinical 
trials in PDAC patients [22, 23]. This therapeutic failure 
might be due to the fact that PDAC also overexpresses 
additional angiogenic factors, such as TGF-β, hepatocyte 
growth factor (HGF), fibroblast growth factors (FGFs), 
platelet derived growth factor (PDGF), and pro-angiogenic 
cytokines [24, 25]. Nonetheless, a recent Phase II clinical 
trial indicated that vatalanib, an inhibitor of VEGF and 
PDGF receptors, slightly improved survival in metastatic 
PDAC [26]. Therefore, the role of angiogenesis in PDAC 
is more complex than previously appreciated and targeting 
multiple-angiogenic pathways may be more effective than 
targeting a single pathway.
We recently established a GEMM of PDAC [27] in 
which mice that express RB with LoxP sites in the introns 
flanking exon 19 were bred with KC mice (Kras-Cre 
recombinase). KC mice carry an oncogenic Kras (KrasG12D) 
allele within its own locus downstream of its endogenous 
promoter and silenced by a LoxP-Stop-LoxP element 
(LSL) upstream of the transcriptional start site [28, 29]. 
The KRC compound mutant mice express oncogenic Kras 
in the pancreas which is devoid of RB due to Pdx1-driven 
Cre recombination (22). KRC mice develop pancreatic 
intraepithelial neoplasia (PanIN) -1 and -2 lesions at 2 
weeks after birth and exhibit rapid PanIN progression to 
murine PDAC (mPDAC) (22) with increased expression of 
several cytokines, such as transforming growth factor betas 
(TGF-βs) and TNF-α, which are also overexpressed in 
human PDAC and are pro-angiogenic [30, 31]. Moreover, 
PDAC in humans is often associated with loss of RB 
function [32], underscoring the potential relevance of the 
KRC GEMM to the human disease.
In the present study, using TCGA data, we 
determine that ~12% of PDACs exhibits a pro-angiogenic 
gene signature. We also establish a novel patient-derived 
orthotopic xenograft (PDOX) model directly from 
samples obtained by fine needle aspiration (FNA) during 
endoscopic ultrasonography (EUS) and demonstrate that 
ECs are present in the original tumor and that these human 
ECs survive when implanted into immunodeficient mice. 
Moreover, we show that KRC mPDACs express a pro-
angiogenic gene signature that overlaps with many of 
the genes in the above TCGA subset, and that inhibiting 
JAK1–2 signaling markedly prolongs survival in this 
model and suppresses cancer progression in vivo, while 
preventing ECs from stimulating PCC growth in culture. 
Therefore, targeting JAK1–2 signaling may be especially 
useful in the subset of PDAC patients that exhibit a pro-
angiogenic gene signature. 
RESULTS
A subset of PDAC patients express a strong 
angiogenesis gene profile and patient-derived 
orthotopic xenografts exhibit tumor angiogenesis
To assess the angiogenic potential of human PDACs 
we analyzed an RNASeq dataset from 85 PDACs in 
The Cancer Genome Atlas (TCGA), focusing on genes 
annotated to angiogenesis Gene Ontology (GO) terms. 
Hierarchical clustering revealed that out of 384 genes 
annotated to angiogenesis, approximately 128 were up-
regulated in some tumors (Figure 1A). We therefore 
extracted this gene set, and performed a second cluster 
analysis to determine whether any patients exhibited 
similar angiogenesis gene expression profiles (Figure 1A). 
Based on this analysis, 10/85 (~12%) PDAC patients 
were identified that harbored tumors in which multiple 
angiogenesis genes were up-regulated, suggesting 
that they exhibit a strong angiogenesis gene signature 
(Figure 1A). By contrast, 59/85 PDACs (~69%) exhibited 
variable expression levels of these genes, suggesting that 
they have a moderate angiogenesis signature, whereas 
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Figure 1: A Subset of Human PDACs exhibit a strong angiogenic gene signature. (A) Hierarchical clustering of TCGA 
data show that genes annotated to angiogenesis (white lines) are up-regulated in some human PDACs (left). Extraction (middle) and 
re-clustering (right) shows that many of these angiogenesis genes are up-regulated in a subset of PDACs (S = strong), whereas some  
(M = moderate) or few of these genes (W = weak) are increased in other PDACs. (B) H&E staining shows cytology of EUS-FNA samples 
(left) and histology of EUS-PDOX tumors in athymic mice. CD31 immunohistochemistry shows that EUS-PDOX tumors harbor ECs in 
the collagen-rich stroma highlighted by Masson’s Trichrome staining of serial sections. (C) Human-specific CD34 (top), VE-Cadherin 
(middle) and CD105 (bottom) antibodies react with ECs in EUS-PDOX tumors, but fail to react with ECs in normal murine pancreata. 
Quantitation (right) of CD31 and Masson’s Trichrome (B), or CD34 (upper), VE-Cadherin (middle) and CD105 (lower panel) (C) pixel 
intensity shows that stroma content and the abundance of ECs in PDOX2 are decreased compared with PDOX1 and PDOX3. Shown in 
(B–C) are representative images from three EUS-PDOX tumors. Insets show magnified images of boxed areas. Scale bars, 50 μm.
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16/85 PDACs (~19%) displayed a weak signature in 
which few genes were elevated (Figure 1A). Differential 
expression analysis of tumors exhibiting a strong signature 
with those exhibiting a weak signature revealed that 77 
angiogenesis genes were significantly up-regulated, 63 of 
which were pro-angiogenic (Supplementary Table 1).
To determine if human PDACs could promote tumor 
angiogenesis in mice, we established a new model in which 
EUS-FNAs were directly implanted into the pancreata of 
athymic mice. Seven tissue samples were obtained by 
EUS-FNA, and all seven patients had suspected PDAC 
at biopsy, which was confirmed by cytology (Figure 1B). 
Of these, 5 formed large intrapancreatic tumors 
(Supplementary Figure 1A) that were palpable within 
2 months, and the mean time to sacrifice was 5.7 ± 1.6 
months. These mice were termed EUS-PDOX mice to 
indicate that they are patient-derived orthotopic xenografts 
generated with EUS-FNAs. Two EUS-PDOX tumors 
were established from EUS-FNAs of resectable tumors, 
and their tumor histopathology was consistent with that of 
the resected tumor, including the formation of mucinous 
ascites from a mucin-producing adenocarcinoma (EUS-
PDOX1; Supplementary Figure 2A). By contrast, the other 
three EUS-PDOX tumors were established from EUS-
FNAs of advanced stage tumors that were unresectable 
(Supplementary Figure 2B).
To evaluate these tumors for angiogenesis we used 
the CD31 endothelial marker. CD31-positive cells were 
present in the stroma of all EUS-PDOX tumors (Figure 1B) 
and in adjacent normal pancreas (Supplementary Figure 
1B). To determine if endothelial cells (ECs) within the 
tumor mass were host- (murine) or biopsy- (human) 
derived, we used a human-specific CD34 antibody that did 
not mark ECs in normal murine pancreata (Figure 1C), or 
in orthotopic tumors generated by intrapancreatic injection 
of human PCCs into athymic mice (Supplementary 
Figure 1C). Consistent with the localization of CD31-
positive cells, CD34 immunoreactivity was present in 
the stromal compartment of all EUS-PDOX tumors 
(Figure 1C). Moreover, human-specific VE-Cadherin and 
CD105 (endoglin) antibodies marked ECs in EUS-PDOX 
tumors (Figure 1C), but were non-reactive with murine 
ECs in normal pancreata (Figure 1C) or in human PCC-
generated orthotopic tumors (Supplementary Figure 1C). 
Thus, the tumor endothelium in first (F0) EUS-PDOX 
tumors that formed was, in part, patient-derived. EUS-
PDOX tumors were either moderately differentiated with 
abundant stroma, or poorly differentiated with a paucity 
of stroma (Figure 1B–1C, Supplementary Figure 2), and 
these histological features were maintained after their first 
in vivo passage (F1; Supplementary Figure 1D). Although 
F1 tumors continued to harbor ECs, these ECs no longer 
expressed any human markers (Supplementary Figure 1D), 
indicating that as these tumors developed and grew they 
were able to readily recruit host-derived ECs.
Quantitation of endothelial and stromal markers in 
EUS-PDOX tumors revealed that tumors with abundant 
stroma, rich in collagens as determined by Masson’s 
trichrome (Figure 1B) and Picosirius red (Supplementary 
Figure 1E), harbored more ECs than stroma-deficient 
tumors (Figure 1B–1C). It has been recently proposed 
that stroma-depleted mPDACs are poorly differentiated, 
but associated with either increased [20] or decreased 
[33] angiogenesis. To clarify this issue and determine 
whether angiogenesis is dictated by the differentiation 
status and extent of desmoplasia in PDAC, we used a 
human PDAC tissue microarray (TMA) in which 26 
tumors were poorly differentiated and 28 were well-to-
moderately differentiated (Figure 2A). Irrespective of 
tumor differentiation, 45/54 tumors were rich in stroma 
(stroma+++), whereas 9 were relatively stroma-deficient 
(stroma+), allowing us to determine if angiogenesis 
correlated with stroma abundance. CD31 or CD34 
immunoreactivity was present in all PDACs (Figure 2B), 
and was strong in 15/54 tumors, but moderate in 20/54 
and weak in 19/54 (Supplementary Figure 3), suggesting 
that some PDACs exhibit robust angiogenesis. However, 
when comparing poorly differentiated with well-to-
moderately differentiated tumors, or stroma-rich vs 
stroma-poor tumors, there were no differences in either 
CD31 or CD34 immunoreactivity between these groups 
(Figure 2C). Therefore, in humans, PDAC angiogenesis 
is not necessarily associated with poorly-differentiated or 
stroma-deficient tumors.
KRC mice exhibit abundant tumor angiogenesis 
and a pro-angiogenic gene signature
KRC mice, which express oncogenic Kras in 
the pancreas, but lack RB function exhibit rapid PanIN 
formation and progression to murine PDAC (mPDAC) 
with a high frequency [27]. Akin to human PDAC, 
which is commonly associated with a high frequency of 
KRAS mutations (95%) and loss of RB function [32], 
KRC mPDACs express high levels of pro-angiogenic 
cytokines [27]. Therefore, we next sought to determine 
whether KRC mPDACs exhibit angiogenesis. As in EUS-
PDOX tumors, CD31 immunoreactivity in KRC mPDAC 
was present in sinusoidal-like blood vessels within the 
collagen-rich stroma adjacent to CK19-positive cancer 
cells (Figure 2D), and in relatively larger blood vessels 
within the stromal compartment (Figure 2E). Moreover, 
intravenous injection of TRITC-conjugated dextran 
followed by intravital imaging using two-photon confocal 
microscopy, demonstrated many dextran-positive vessels 
(Figure 2F), confirming the presence of blood flow.
We next conducted an array analysis using KRC 
tumor-derived RNA to determine if they exhibit a pro-
angiogenic gene expression profile. Gene Ontology (GO) 
analysis revealed that KRC tumors exhibited significant 
enrichment of pro-angiogenic processes (Supplementary 
Figure 4A). Moreover, gene set enrichment analysis 
(GSEA) indicated that these genes were often the same 
as those up-regulated in human PDACs with a strong 
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Figure 2: Subsets of Human PDACs and KRC murine PDACs exhibit angiogenesis. (A) H&E staining shows that tumors in a 
human PDAC tissue microarray exhibit poor or well-to-moderate differentiation, and that some have abundant stroma (stroma+++), whereas 
others are relatively stroma-deficient (stroma+). (B) ECs are present in poor and well-moderately differentiated PDACs as evidenced by 
the presence of CD31 (top) and CD34 (lower) immunoreactivity. Insets show magnified images of boxed areas. Shown in (A–B) are 4/54 
human PDACs. (C) Pixel intensity quantitation shows CD31 (top) and CD34 (bottom) immunoreactivity is similar when comparing poor 
(closed bars) with well-moderate (open bars) PDACs, or when comparing stroma+++ (gray bars) with stroma+ (hatched bars) PDACs. 
Data are presented as mean ± SEM. (D) KRC mPDACs harbor ECs adjacent to CK19-positive cancer cells in the collagen-rich stroma as 
evidenced by Masson’s Trichrome staining of serial sections. Quantitation (right) of CD31 and Masson’s Trichrome staining shows that 
EC abundance and stromal content increases from postnatal months 2 to 4. (E) CD31-positive vessels are also present throughout KRC 
mPDACs. Shown in (D–E) are representative images from 5 KRC mice at each age. Insets in (B, D–E) are magnified images of boxed areas. 
Scale bars, 50 μm. (F) Intravital microscopy shows that KRC tumors have blood flow as evidenced by the abundance of dextran-positive 
(red) vessels. Shown is a representative image from 1 of 2 KRC mice. (G) Gene set enrichment analysis (GSEA) comparing KRC tumor 
array data with TCGA data shows that genes up-regulated in KRC tumors correlate with genes up-regulated in the strong pro-angiogenic 
gene signature subgroup (family-wise error rate (FWER) < 0.001).
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angiogenesis gene signature (Figure 2G). Thus, compared 
with the 77 gene TCGA signature, 42 genes were 
differentially expressed in KRC tumors, 37 of which 
were pro-angiogenic (Supplementary Table 2). Together, 
these data suggest that like human PDAC, KRC mPDACs 
exhibit a robust pro-angiogenesis signature.
A pro-angiogenic gene signature is present in 
KRC PCCs
Increased expression of pro-angiogenic genes 
in KRC tumors could arise as a consequence of their 
up-regulation in the cancer cells. Therefore, we next 
evaluated KRC-derived PCCs for a pro-angiogenic 
gene expression profile. Accordingly, we conducted a 
GO analysis of microarray data comparing KRC PCCs 
with PCCs derived from KC tumors, which also express 
oncogenic Kras, but retain RB function and express low 
levels of pro-angiogenic cytokines [32]. KRC PCCs 
exhibited significant enrichment of pro-angiogenic 
processes (Supplementary Figure 4B), and increased 
expression of 47 pro-angiogenic genes (Supplementary 
Table 3). By contrast, only 8 anti-angiogenic genes were 
differentially expressed, 4 of which were down-regulated 
(Supplementary Table 3). qPCR validated the arrays and 
confirmed that KRC tumors and PCCs expressed relatively 
high levels of Ctgf, Cyr61, Egfr, Nrp2, Serpine1, Tgbr1 
and Vegfc mRNA (Supplementary Figure 4C–4D). By 
contrast, Vegfa mRNA levels were similar in KRC and KC 
cells, in agreement with the observation that oncogenic 
Kras, per se, can up-regulate Vegfa mRNA expression [34]. 
Thus, KRC tumors and PCCs exhibit increased expression 
of multiple pro-angiogenic factors which are reflective of 
the gene expression profile seen in human PDAC.
TGF-β promotes angiogenesis indirectly
We next assessed the ability of conditioned media 
(CM) from KRC cells to enhance the proliferation and 
migration of murine SVEC4–10 ECs that are commonly 
used to study angiogenesis pathways in vitro [35]. CM 
from three KRC-derived PCCs markedly enhanced EC 
proliferation and migration (Figure 3A), suggesting 
that KRC cells may secrete factors that promote EC 
proliferation in vivo. To identify mechanisms through 
which KRC cell-derived factors could promote 
angiogenesis in vivo, we conducted an Ingenuity Pathway 
Analysis (IPA) of our KRC tumor array data. Based on 
the overall gene expression profile of KRC tumors, IPA 
identified TGF-β as the top regulator of gene expression 
(P = 1.91 × 10−16). GSEA confirmed these findings, 
and indicated that genes up-regulated in KRC tumors 
correlated strongly with genes up-regulated by TGF-β 
(Figure 3B). Moreover, KRC mPDACs (Figure 3C) and 
human PDACs [32] are often associated with nuclear 
p-Smad2 and p-Smad3, indicating that canonical TGF-β 
signaling pathways are active in both settings, and raising 
the possibility that PDAC-derived TGF-βs could promote 
angiogenesis [36].
KRC PCCs also exhibit a gene expression profile 
that reflects active TGF-β signaling [32]. Moreover, in a 
syngeneic orthotopic model using KRC cells, inhibition 
of TGF-β attenuates tumor growth and metastasis, and 
markedly prolongs survival [32]. Inasmuch as blocking 
TGF-β signaling suppresses tumor angiogenesis in 
immune-deficient orthotopic models using human PCCs 
[37], we next evaluated the consequences of TGF-β 
type I receptor (TβRI) kinase inhibition with SB505124 
on angiogenesis in a syngeneic KRC orthotopic model. 
Compared with vehicle-treated tumors, CD31 and CD34 
immunoreactivity was attenuated in the tumors of mice 
treated with SB505124 a (Figure 3D), suggesting that 
TGF-β signaling enhances angiogenesis in these tumors 
in vivo. These pro-angiogenic actions could be due to 
direct effects on ECs, or through the up-regulation of pro-
angiogenic genes in the PCCs and cells within the tumor 
microenvironment (TME). To explore whether TGF-β 
acted directly on ECs, we next assessed the ability of CM 
derived from KRC PCCs to activate canonical TGF-β 
signaling in SVEC4–10 ECs. Indeed, KRC-derived CM 
increased Smad2 and Smad3 phosphorylation in ECs, 
which was blocked by SB505124 (Figure 3E), pointing 
to TGF-β pathway activation in the ECs. However, 
SB505124 failed to block the ability of KRC-derived CM 
to stimulate EC proliferation or migration (Figure 5F), 
indicating that TGF-β does not directly enhance 
angiogenesis.
STAT3 is active in tumor endothelial cells
Analysis of KRC PCC array data revealed that 
34 of the 47 pro-angiogenic genes up-regulated in KRC 
cells were predicted to be TGF-β targets (Supplementary 
Table 3). To determine if TGF-βs promote pro-angiogenic 
gene expression in KRC cells, we suppressed TβRI 
signaling with SB505124, and assayed Ctgf and Wisp1, 
which were elevated in the human PDACs with a pro-
angiogenic signature, and Cyr61, Pdgfa and Vegfc, which 
are known to promote angiogenesis and which have also 
been reported to be expressed at high levels in human 
PDAC [25, 38, 39]. SB505124 markedly suppressed the 
levels of all five mRNAs (Figure 3G). Moreover, out of 
25 cytokines assayed by multiplex ELISA, only CXCL1, 
CXCL5, MCP-1, GM-CSF, VEGF-A and VEGF-C were 
readily detected in KRC CM, and TGF-β1 increased the 
levels of the latter three (Figure 3H, Supplementary Table 
4). Importantly, TGF-β increased GM-CSF by 14.7-fold 
and VEGF-A by 42-fold, whereas IL6, a potent inducer of 
STAT3, was below the level of detection (Supplementary 
Table 4). All six of the detectable factors are pro-
angiogenic and activate STAT3, an oncogene and survival 
factor that can be activated by many additional cytokines 
and growth factors [40, 41], that has been implicated 
in promoting tumor angiogenesis [42] and modulating 
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Figure 3: TβRI inhibition does not block endothelial activation but suppresses angiogenic gene expression in PCCs.  
(A) Compared with control media (closed bars), conditioned media (CM) from three KRC cell lines (purple, green or blue bars) significantly 
enhance EC proliferation (top) and migration (bottom). (B) GSEA shows that genes up-regulated in KRC tumors correlate with genes 
up-regulated by TGF-β (FWER < 0.001). (C) Canonical TGF-β signaling pathways are active in KRC tumors as evidenced by the 
abundance of nuclear p-Smad2 (top) and p-Smad3 (bottom). (D) Vehicle-treated tumors (top) display abundant CD31 (left) and CD34 
(right) immunoreactivity, both of which are markedly attenuated in SB505124-treated tumors. Shown in (C–D) are representative images 
from 3 mice per group. Scale bars, 50 μm. (E) CM from KRC cells markedly increase p-Smad2 and p-Smad3 levels in ECs, which is 
blocked by SB505124 [2 μM]. Shown are representative immunoblots from three independent experiments. (F) SB505124 [2 μM] does not 
prevent KRC CM from enhancing EC proliferation (top) or migration (bottom). Data in (A, F–H) are mean ± SEM. **P < 0.01; *P < 0.05. 
(G) SB505124 (2 μM] significantly attenuates the levels of the indicated mRNAs in KRC PCCs. (H) ELISA shows the levels of the indicated 
cytokines in KRC CM in the absence (open bars) or presence (closed bars) of TGF-β1. Data are mean ± SD from two different cell lines.
Oncotarget7511www.impactjournals.com/oncotarget
the TME [43]. Therefore, we next sought to determine 
whether STAT3 is active in the endothelium of KRC, 
EUS-PDOX and human tumors. Indeed, phosphorylated 
STAT3 (p-STAT3) was not only abundant in the nuclei 
of PCCs and cancer-associated fibroblasts (CAFs) in 
KRC tumors, but was also frequently present in ECs, 
identified using a murine-specific VE-Cadherin antibody 
(Figure 4A). Similarly, a human-specific VE-Cadherin 
antibody revealed that nuclear p-STAT3 was present 
in ECs in EUS-PDOX tumors, and in all VE-Cadherin-
positive vessels seen in 32/54 (59%) human PDAC tissues 
(Figure 4A). Thus, STAT3 activation is common in PDAC 
endothelia.
STAT3 is required for endothelial cell activation 
by PCCs
We next determined if PCC-derived factors activate 
endothelial STAT3 by using CM from KRC PCCs. CM 
robustly increased STAT3 phosphorylation and STAT3-
dependent transcription in ECs (Figure 4B–4C), which 
was completely blocked by the JAK1–2 inhibitor, 
ruxolitinib, or by silencing STAT3 in ECs with a shRNA 
that suppressed STAT3 to undetectable levels (Figure 4C). 
Ruxolitinib and STAT3 silencing also blocked the ability 
of CM to stimulate EC proliferation (Figure 4D). To 
determine if these inhibitory effects were associated with 
impaired up-regulation of pro-angiogenic genes within 
ECs, we next focused on HDAC9, since it was present 
in both human and KRC pro-angiogenic gene signatures, 
and is required for EC sprouting and tube formation in 
vitro and vessel formation in vivo [44]. Hdac9 mRNA 
levels were readily detectable in SVEC4–10 ECs, but 
were significantly reduced in STAT3-silenced ECs 
(Figure 4E). Moreover, STAT3 silencing or ruxolitinib 
prevented KRC CM from significantly increasing Hdac9 
mRNA levels (Figure 4F). Conversely, transfection of 
murine Hdac9 cDNA into STAT3-silenced ECs restored 
the ability of KRC CM to stimulate the growth of these 
cells (Figure 4G). Together, these results suggest that 
KRC-derived factors promote EC growth through STAT3-
dependent pathways that are required for up-regulation of 
pro-angiogenic genes in ECs, including STAT3-mediated 
upregulation of HDAC9, which stimulates EC growth
Given that STAT3 enhanced HDAC9 expression in 
cultured ECs, and that STAT3 is active in PDAC ECs, we 
next sought to determine whether HDAC9 was present in 
ECs in human and KRC tumors. HDAC9 was abundant 
in both PCC and CAF nuclei in human PDACs, and in 
CD31-positive blood vessels in these tissues (Figure 4H). 
HDAC9 was also abundant in nuclei of cancer cells, CAFs 
and CD31-positive vessels in EUS-PDOX tumors and 
KRC mPDACs (Figure 4H). Moreover, in ECs derived 
from KRC tumors that were devoid of the epithelial 
marker CK19 but express the endothelial marker CD34, 
Hdac9 mRNA levels were increased 18-fold compared 
with the levels in SVEC4–10 ECs (Figure 4I), suggesting 
that HDAC9 is present at high levels PDAC ECs.
Ruxolitinib attenuates PDAC growth and 
prolongs survival
Endothelial recruitment and growth is an important 
aspect of tumor biology, including the progression of 
pre-malignant lesions to cancer [45]. KRC mice develop 
acinar-to-ductal metaplasia (ADM) and PanIN lesions 
that rapidly and frequently progress to mPDAC [27]. 
Moreover, lesion initiation and progression occurs in 
conjunction with the appearance of inflammatory infiltrates 
and increased cytokine expression [27]. Therefore, we next 
used this GEMM to determine if inhibiting JAK1–2 with 
ruxolitinib could act to impede angiogenesis and suppress 
PanIN progression and mPDAC growth. Accordingly, 
we administered ruxolitinib to KRC mice at postnatal 
month 1, an age at which ADM, PanIN and mPDAC are 
commonly observed in the pancreas (Figure 5A). After 3 
weeks of therapy, we evaluated their pancreata for extent 
and severity of disease. All vehicle-treated mice exhibited 
multiple foci of ADM, PanIN and mPDAC (Figure 5B) 
that occurred in conjunction with strong, nuclear p-STAT3 
immunoreactivity (Figure 5C). The cancer cells and 
ADM were proliferative as evidenced by the presence 
of nuclear phosphorylated Histone H3 (p-Histone H3), 
and were surrounded by an abundance of CD31-positive 
ECs (Figure 5C). Moreover, ECs in vehicle-treated 
mice frequently harbored nuclear p-STAT3 and HDAC9 
(Figure 5D). Remarkably, the pancreata of KRC mice 
receiving ruxolitinib were mostly normal, and only 
displayed small foci of ADM (Figure 5B) that exhibited 
weak p-STAT3 immunoreactivity and markedly 
attenuated proliferation, and were associated with 
few ECs (Figure 5C) in which nuclear p-STAT3 and 
HDAC9 immunoreactivity was markedly attenuated 
(Figure 5D). Moreover, in a survival study, 100% of 
ruxolitinib-treated mice were alive and healthy at postnatal 
week 14, with only one mouse succumbing at postnatal 
week 15 (Figure 5E). By contrast, all vehicle-treated mice 
succumbed by postnatal week 8.5 (Figure 5E). Therefore, 
ruxolitinib attenuates ADM progression to PanIN and 
mPDAC, while suppressing angiogenesis and markedly 
prolonging survival in this autochthonous model.
In contrast to KRC tumors, mPDACs arising in 
KPC mice which express oncogenic Kras together with 
mutated p53, did not exhibit Hdac9 up-regulation or a 
pro-angiogenic gene signature that was present in KRC 
and human PDACs (Supplementary Figure 5A–5B). 
Therefore, we next used this GEMM to determine whether 
targeting JAK1–2 with ruxolitinib suppresses PanIN 
progression and mPDAC growth in a GEMM lacking 
tumor angiogenesis [46]. We administered ruxolitinib to 
KPC mice at postnatal month 3 when they often exhibited 
ADM, PanIN and mPDAC (Supplementary Figure 5C). 
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Figure 4: STAT3 is active in PDAC tumor endothelia and enhances HDAC9 expression to promote endothelial 
proliferation. (A) p-STAT3 (red) is abundant in the nuclei of VE-Cadherin-positive vessels (green, outlined) and surrounding stromal 
cells (arrowheads) in KRC (top), EUS-PDOX tumors (middle), and human PDACs (bottom). (B) KRC CM markedly increases p-STAT3 
levels in ECs, which is blocked by ruxolitinib [100 nM]. (C) KRC CM significantly enhances STAT3 luciferase reporter activity in ECs (top), 
which is blocked by ruxolitinib [100 nM] or a STAT3-targeting shRNA (shRNA#2). Immunoblotting (lower panel) shows the knockdown 
efficiency of STAT3-targeting shRNAs. ERK2 confirms equivalent lane loading. Shown in (B–C) are representative immunoblots from 
three independent experiments. (D) CM from KRC cells significantly enhances EC proliferation, but in the presence of ruxolitinib ([100 
nM], left) or in ECs transduced with a STAT3-targeting shRNA#2 (right) CM fails to enhance EC proliferation. (E) Hdac9 mRNA levels 
are significantly decreased in ECs transduced with STAT3-targeting shRNA#2 (open bar). (F) CM from KRC cells significantly increases 
Hdac9 mRNA levels in ECs, but in the presence of shRNA#2 or ruxolitinib [100 nM] CM fails to up-regulate Hdac9. (G) CM fails to 
stimulate the proliferation of ECs transduced with shRNA#2, but when these ECs are transfected with an Hdac9 cDNA construct, CM 
significantly enhances EC proliferation. (H) HDAC9 (red) is abundant in the nuclei of CD31-positive vessels (green, outlined) and in 
surrounding stromal (arrowheads) and cancer cells (arrows) in EUS-PDOX (middle) and KRC PDACs (bottom) as evidenced by co-
localization with DAPI (blue) in CD31-cadherin-positive vessels (outlined). (I) Compared with SVEC4–10 ECs, Hdac9 and Cd34 are 
significantly increase in KRC tumor-derived ECs, whereas Ck19 is absent in both. Shown in (A) and (H) are representative images from 
three KRC or EUS-PDOX tumors, or the TMA. Scale bars, 50 μm. Data in (C–G, I) are mean ± SEM. *P < 0.05, and **P < 0.01.
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After 3 weeks of therapy, pancreatic histology from 
vehicle- and ruxolitinib-treated mice were similar, and 
frequently exhibited abundant ADM, PanIN and mPDACs, 
with many p-Histone H3-positive nuclei but few CD31-
positive ECs (Supplementary Figure 5D–5E). Therefore, 
ruxolitinib failed to suppress cancer cell proliferation or 
mPDAC progression in KPC mice.
To determine if ruxolitinib exerts tumor 
suppressive effects in KRC mice by targeting the 
endothelium, the neoplastic epithelium, or both 
compartments, we next co-cultured fluorescently-labeled 
SVEC4–10 ECs and KRC PCCs in a 3-dimensional 
(3D) culture system [32]. Remarkably, PCC growth 
was enhanced in the co-culture model compared with 
3D cultures in which PCCs were cultured separately 
from ECs, and this enhanced growth in co-culture was 
completely suppressed by ruxolitinib (Figure 6A). By 
contrast, ruxolitinib failed to inhibit the growth of either 
PCCs or ECs when cultured separately (Figure 6B). 
Thus, ECs can enhance PCC growth through an 
angiocrine mechanism, which is suppressible by 
targeting JAK1–2 with ruxolitinib (Figure 6C).
Figure 5: Ruxolitinib suppresses mPDAC progression and prolongs survival of KRC mice. (A–B) H&Es show that KRC 
pancreata often exhibit ADM, PanIN and mPDAC at postnatal month 1 (A), and that vehicle-treated mice display abundant lesions and 
mPDAC, whereas ruxolitinib-treated pancreata are mostly normal and only display small foci of ADM (B) Shown are representative 
images from two mice per group. Right panels are high magnification images of boxed areas. (C) Nuclear p-STAT3 (left) is abundant in 
KRC mPDACs (top) and ADM (middle) in vehicle-treated mice, whereas ADM in ruxolitinib-treated mice (bottom) have weak p-STAT3 
immunoreactivity. mPDACs and ADM in vehicle-treated mice also have abundant ECs and are highly proliferative as evidenced by the 
presence CD31 and p-Histone H3 immunoreactivity, respectively. ADM in ruxolitinib-treated mice have few CD31-positive ECs, and 
p-Histone H3 is mostly absent. (D) VE-cadherin-positive ECs (green) in vehicle-treated KRC mice harbor nuclear p-STAT3 (top panels, 
red, arrows), whereas ECs in ruxolitinib-treated mice lack nuclear p-STAT3 (arrowheads). CD31-positive ECs vehicle-treated KRC mice 
also exhibit strong, nuclear HDAC9 immunoreactivity (bottom panel, red, arrows) that is markedly attenuated in ECs in ruxolitinib-treated 
mice (arrowheads). All images were acquired using the same exposure time. Scale bars in (A–D), 50 μm. (E) Kaplan-Meier analysis shows 
that compared to vehicle (red line), ruxolitinib (blue line) significantly (P = 0.018) prolongs survival of KRC mice. Dashed line indicates 
that 2 ruxolitinib-treated mice were alive beyond postnatal week 18.
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DISCUSSION
It is projected that PDAC will become the second 
leading cause of cancer death in the US by 2030 [47]. It 
is crucial, therefore, to develop a personalized therapeutic 
approach for PDAC. However, this is a daunting task 
given the complexity of the molecular alterations and 
mutations in PDAC. Moreover, only ~20% of patients 
undergo resection, and tissue biopsies obtained from 
the remaining PDAC patients (~80%) are generally too 
small for molecular analysis such as deep sequencing or 
RNASeq, in part due to the clinical imperative to analyze 
the samples in a manner that assures adequate patient care. 
Importantly, these samples consist of a mixed population of 
cells with extensive stroma, resulting in a paucity of cancer 
cells within the biopsy sample. By contrast, fragments 
Figure 6: Ruxolitinib suppresses mitogenic cross-talk between endothelial cells and PCCs. (A) 3D co-cultures of ECs (red) 
and KRC PCCs (green) shows that compared with vehicle (DMSO, left), ruxolitinib ([100 nM], right) suppresses PCC growth. Shown are 
representative phase contrast and fluorescent images taken on day 8. Scale bars, 200 μm. (B) Fluorescence intensity quantitation shows that 
compared with 3D cultures in which ECs and PCCs are cultured independently (single culture), culturing ECs and PCCs together in 3D 
(co-culture) significantly enhances PCC growth, which is blocked by ruxolitinib (open bars). Data are mean ± SEM from three independent 
experiments. *P < 0.05, and **P < 0.01. (C) Schematic representation of PCC and EC cross-talk. TGF-β activates canonical Smad-
dependent signaling in PCCs (top) leading to enhanced production of pro-angiogenic factors, which can be blocked by SB505124. These 
factors activate JAK/STAT3 signaling in ECs (bottom), which promotes EC proliferation through HDAC9, and ruxolitinib blocks these 
effects. ECs also produce factors (angiocrine factors) that can exert growth-stimulatory effects on PCCs through JAK/STAT3 signaling, 
which can also be targeted with ruxolitinib.
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from surgically resected samples can be implanted 
subcutaneously in immune-deficient mice to yield patient-
derived xenografts (PDX), allowing the cancer cells to grow 
in vivo in sufficient quantities for investigators to conduct 
extensive cancer genome analyses [48]. Here we show that 
directly implanting EUS-FNA-derived samples into the 
pancreas of immune-deficient mice yields viable human 
orthotopic tumors termed PDOX.
Tumor angiogenesis is generally not believed to play 
a role in PDAC pathobiology. However, our transcriptome 
analysis of TCGA data served to identify a subset of 
PDACs exhibiting a strong angiogenic gene signature, and 
we used the PDOX model to confirm that angiogenesis 
occurs in PDAC. Thus, we determined that in their earliest 
in vivo passage (F0), PDOX tumors harbor many human 
ECs, pointing to their presence in the original tumors and 
underscoring their ability to survive for many months in 
the tumor microenvironment in this model. The intra-
pancreatic location of the PDOX tumors avoids the issues 
that may occur with subcutaneous PDX models where blood 
flow derives from the subcutaneous compartment which is 
not relevant to PDAC. Importantly, PDOX tumors can be 
established from all PDAC patients, including the 80% of 
patients who are ineligible for surgical resection, and they 
can be established using relatively small tissue biopsies to 
generate tumors that recapitulate histological features of 
the original patient tumor, including moderate or poorly 
differentiated tumors with varying degrees of desmoplasia. 
Thus, our PDOX model could be useful for testing drug 
responses and designing strategies for personalized medicine.
mPDACs arising in KIC mice which express 
oncogenic Kras and are devoid of the Ink4a locus encoding 
p16 exhibit angiogenesis histologically and express pro-
angiogenic factors [49]. In the present study we determined 
that KRC mice, which harbor oncogenic Kras and are 
devoid of RB [27], also exhibited tumor angiogenesis and 
a pro-angiogenic gene signature that partly overlapped with 
genes expressed at high levels in the angiogenic subset of 
TCGA PDACs, as further confirmed by GSEA. Moreover, 
intravital microscopy established the presence of blood flow 
in the KRC tumors, similar to observations in animal models 
of vascular human cancers [50, 51]. By contrast, KPC mice 
develop hypovascular mPDACs that have minimal blood 
flow [17, 46, 52], KTC mice (oncogenic Kras with deletion 
of the type II TGF-β receptor) exhibit tumor angiogenesis 
[33], whereas in KPfl/+CY mice (oncogenic Kras and 
heterozygous p53 loss) exhibit suppressed angiogenesis 
[20]. Although targeting the stroma in KTC and KPfl/+CY 
mice promotes undifferentiated mPDAC, our current analysis 
of human PDACs did not demonstrate a clear correlation 
between tumor angiogenesis and either stroma abundance 
or tumor differentiation. Taken together, these observations 
point to marked differences in tumor angiogenesis among 
different GEMMs of PDAC, and suggest that our PDOX 
model accurately reflects the status of tumor angiogenesis 
in PDAC patients. Moreover, given that KRAS and p16 are 
the two most commonly mutated genes in PDAC, and that 
RB dysfunction is also common in PDAC [32], KRC mice 
could be a useful GEMM for studying angiogenesis that 
reflects events in PDAC patients whose cancers exhibit a 
pro-angiogenic signature.
In assessing the mechanisms that promote 
angiogenesis in the KRC GEMM, we determined that CM 
from KRC PCCs enhanced EC growth and migration, and 
activated canonical TGF-β and STAT3 pathways in cultured 
SVEC4–10 ECs. Although TGF-β and STAT3 are known to 
enhance tumor angiogenesis [36, 53, 54], TβRI inhibition 
with SB505124 did not suppress endothelial activation in 
vitro. Instead, it decreased the expression of several pro-
angiogenic factors in KRC PCCs and suppressed mPDAC 
angiogenesis in vivo. Thus, the pro-angiogenic actions 
of TGF-βs in KRC mPDAC are not due to a direct effect 
by TGF-β on ECs. By contrast, JAK1–2 inhibition with 
ruxolitinib or STAT3 silencing prevented PCC-derived 
factors from enhancing STAT3-dependent transcription, as 
determined in a STAT3 luciferase reporter assay. Moreover, 
STAT3 silencing attenuated HDAC9 expression, and 
prevented CM from up-regulating HDAC9 in ECs. HDAC9 
is a member of the class II family of histone deacetylases 
that includes HDACs 6 and 7, and all three HDACs exert 
pro-angiogenic effects in ECs [55–57]. Whereas HDAC6 
and 7 were not part of the pro-angiogenic signatures in 
human PDACs or KRC mPDACs, HDAC9 was part of 
both signatures, was abundant within ECs in human PDAC, 
and in PDOX and KRC tumors, and enabled PCC-derived 
factors to stimulate proliferation of ECs that lack STAT3. 
Thus, HDAC9 promotes angiogenesis downstream of 
STAT3 and could serve as a marker of angiogenesis and 
endothelial STAT3 activation in PDAC.
Our findings thus point to a model in which TGF-
βs promote the expression of pro-angiogenic factors in 
PCCs that, in turn, activate ECs through STAT3-dependent 
pathways (Figure 6C). Two distinct observations support 
this conclusion. First, the pro-angiogenic signature in KRC 
mPDACs correlated with an active TGF-β gene signature, as 
determined by GSEA. Second, TGF-β increased the levels of 
STAT3-activating pro-angiogenic cytokines in KRC-derived 
CM, including VEGF-A and GM-CSF. Oncogenic Kras has 
been previously shown to upregulate VEGF-A [58] and GM-
CSF expression [59]. Importantly, in addition to enhancing 
angiogenesis, GM-CSF can promote mPDAC progression 
by recruiting myeloid-derived suppressor cells (MDSCs) 
which antagonize cancer-directed immune mechanisms 
[59, 60]. Thus, suppressing TGF-β pathways in PDAC can 
lead to attenuated angiogenesis and enhanced cancer directed 
immune activity by attenuating GM-CSF expression and by 
suppressing the direct actions of TGF-β on immune cells.
EC-derived factors are known to promote the 
proliferation of epithelial-type cells through paracrine 
interactions during hepatic cell regeneration [61], and in 
lymphoma [62], ovarian cancer [63], and breast cancer 
[64]. Using a 3D co-culture system we demonstrated for 
the first time that activated ECs promote PCC proliferation, 
and that this action is mediated by STAT3-dependent 
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pathways. STAT3 is a known oncogene and survival factor 
that promotes cancer cell proliferation, tumor angiogenesis, 
and inflammation [53, 54, 65]. Moreover, when oncogenic 
Kras is combined with loss of p53, both EGFR and STAT3 
must be suppressed to block mPDAC development [66], 
underscoring the importance of STAT3 in the earliest stages 
of PDAC progression. STAT3 is activated by JAK1–2, and 
the JAK1–2 inhibitor ruxolitinib has been approved by the 
FDA for the treatment of myelofibrosis and polycythemia 
vera, and is currently being tested in pancreatic and breast 
cancer clinical trials. In addition to modulating PCC-
autonomous actions, and cancer-associated inflammatory 
signaling, our findings suggest that STAT3 acts in ECs 
to promote tumor angiogenesis, and facilitate angiocrine 
actions. Thus, it was important to assess the consequences of 
ruxolitinib administration in the KRC GEMM. Impressively, 
when administered at an age when mPDAC has already 
developed, ruxolitinib suppressed tumor angiogenesis and 
disease progression in KRC mice, dramatically prolonging 
their survival. By contrast, ruxolitinib did not have any 
beneficial effects in KPC mice, which are hypovascular and 
did not exhibit a pro-angiogenic gene signature.
The current findings suggest that targeting JAK1–2 
with ruxolitinib could attenuate the proliferation of PCCs 
and associated ECs while dampening the actions PDAC-
associated inflammatory cells and inflammatory cytokines, 
especially in those patients whose cancers express a strong 
pro-angiogenic signature. Taken together with recent 
encouraging Phase II data in metastatic PDAC using 
vatalanib, which targets pro-angiogenic VEGFRs and 
PDGFRs [26], and ruxolitinib [67], our TCGA analysis 
and the KRC GEMM data raise the possibility that 
PDAC patients should be selected for anti-angiogenesis 
therapy based on their pro-angiogenic gene signature. Our 
findings also suggest that ruxolitinib may be especially 
effective because it targets the JAK-STAT3 pathway 
that is downstream of multiple pro-angiogenic factors, 
and suggest that selection of patients for this type of 
therapeutic targeting may also exert beneficial actions by 
interrupting growth-promoting angiocrine pathways.
METHODS
Cell lines and conditioned media
KRC cells were cultured as described [32]. SVEC4–
10 ECs were obtained from ATCC (CRL-2181). PANC-1 
(CRL-1469) pancreatic cancer cells were established 39 
years ago [68], and Panc 08.13 (CRL-2551) were established 
more recently [69]. Both are from primary pancreatic 
adenocarcinomas [68], have KRASG12D mutations [69, 70], 
and were obtained from ATCC. ECs and human PCCs were 
cultured in DMEM supplemented with 1% antibiotic (100 
units/ml penicillin; 100 mg/ml streptomycin), and FBS (10%/
ECs; 5%PCCs). KRC tumor ECs were established from 2 
month-old KRC pancreata as described [49]. All cell lines 
were confirmed to be mycoplasma-free using the Mycoalert 
detection kit (Lonza). For conditioned media (CM), KRC 
cells were seeded in 10 cm tissue culture plates (BD Falcon). 
72 h post-serum starvation, media was collected, centrifuged 
and filtered through a 0.22 μm syringe filter.
Mice
KRC and KPC mice were generated and 
maintained as described [16, 32]. For intravital imaging, 
Tetramethylrhodamine (TRITC)-conjugated Dextran (80 
mg/kg) and Hoescht (10 mg/kg) were prepared in sterile 
saline, and injected into the tail vein of anesthetized KRC 
mice. A lateral incision was made, and the pancreas was 
exposed and imaged using a Leica TCS SP8 confocal 
microscope. Mice remained under anesthesia for the 
entire experiment. For therapeutic studies, 8 KRC mice 
or 8 KPC mice were randomized into ruxolitinib (4 mice) 
or vehicle control (4 mice) groups at postnatal weeks 4 or 
12, respectively. For survival studies, 7 KRC mice were 
randomized into ruxolitinib (4 mice) or vehicle control (3 
mice) groups. Ruxolitinib [50 mg/kg] or equal volumes of 
vehicle (0.5% hydroxypropyl methylcellulose (HPMC)) 
were administered to mice by daily gavage. All mice were 
genotyped twice (pre-weaning and post-necropsy).
To establish EUS-PDOX tumors, all patients signed 
informed consent and Dr. Cote and Dr. Sherman performed 
EUS-FNA procedures and placed them into DMEM/F12 
supplemented with 2% antibiotic-antimycotic solution (Life 
Technologies). Two tissue fragments (1mm3 each) were 
washed 5x in media containing antibiotic-antimycotic, then 
implanted into the pancreata of 8 week old, male athymic 
mice (Harlan Laboratories). Human PCC orthotopic models 
were established by injecting 500,000 PANC-1 or Panc 
08.13 cells into the pancreata of 8 week old athymic mice. 
All mouse studies were approved by the Institutional Care 
and Use Committee of Indiana University.
Immunostaining
Pancreata from KRC mice were harvested at the 
indicated time points, and EUS-PDOX tumors were 
harvested as mice became moribund. Immunohistochemistry 
was performed as described [32]. Details, including 
antibodies and dilutions used are provided in the 
Supplementary Methods. For quantification, images were 
obtained at 20x magnification from 5 different fields using 3 
mice using an Olympus BX60 microscope and a QImaging 
ExiBlue camera. Overall positive pixel intensity was 
determined using ImageProPlus v7.0 (Media Cybernetics). 
Quantitation data are presented as mean pixel intensity ± 
SEM. The human PDAC TMA was obtained from the Tissue 
Procurement and Distribution core at the Indiana University 
Simon Cancer Center. Scoring for stromal content was 
performed as described [10, 49, 71]. Briefly, tumors were 
scored independently by two investigators (J.G. and M.K.) 
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for percentage of stromal content: + = 0–33%, ++ 33–67% 
and +++ = > 67%. Quantitation of immunohistochemistry 
using the TMA was performed using positive pixel count in 
Aperio Imagescope software. Approval for acquisition of the 
human PDAC TMA was granted by the Office of Research 
Administration at Indiana University.
ELISA
KRC cells were seeded in 6-well plates (200,000/
well). After 24 h, cells were serum-starved overnight, and 
treated with control media or TGF-β1 [0.5 nM] for 24 h. 
CM was prepared, and levels of the indicated cytokines 
were determined using a Milliplex ELISA kit (Millipore) 
per the manufacturer’s recommendation. 
Microarrays
Array analysis of total RNA from KC and KRC cells 
was previously described [32]. Array analysis of KRC and 
KPC tumors was performed by Miltenyi Biotec. Briefly, 
Agilent whole mouse genome microarrays were performed 
using total RNA from 4 month-old KRC or 3 month-old 
KPC tumors (Cy5-labeled), or age- and sex-matched 
normal pancreata (Cy3-labeled). Details are provided in 
the Supplementary Methods. Data will be made available 
in the GEO database.
TCGA analysis
RNASeq RSEM [72] normalized reads and raw count 
reads from the pancreatic ductal adenocarcinoma dataset 
(abbreviated PAAD) was downloaded from The Cancer 
Genome Atlas (TCGA) from http://cancergenome.nih.gov/. 
Details are provided in the Supplementary Methods.
Quantitative PCR
Quantitative PCR (qPCR) was performed for the 
indicated mRNAs using Taqman gene expression assays 
(Life Technologies) and cDNA prepared from total RNA 
as described [27, 32]. β-actin and Rps6 served as the 
endogenous controls for cells and tumor tissues, respectively.
Cell proliferation
Cell proliferation was assessed by MTT [73]. Briefly, 
ECs (5,000/well) were seeded in 96-well plates, serum-
starved, and media was replaced with serum-free media 
(control) or CM from KRC cells. For inhibitor studies, 
SB505124 [2 μM], ruxolitinib [100 nM] or DMSO [0.05%] 
were added to control and conditioned media. STAT3 
knockdown was performed as described [74] by transducing 
ECs with two shRNAs that target murine STAT3 [75] or 
a non-targeting shRNA control (Thermo Scientific). 
An HDAC9 cDNA construct (Origene) was transfected 
into ECs using Lipofectamine 2000 (Life Technologies) 
per manufacturer’s recommendations. An empty vector 
(pCMV6) was transfected as a control. Proliferation was 
assessed at 48 h. The mean of control-treated cells was 
normalized to 100%, and changes in proliferation were 
calculated as % control in three independent experiments.
Migration
Migration was assessed using a Boyden chamber 
assay. ECs (20,000) were seeded in 8.0 μm cell culture 
inserts (BD Biosciences) in serum-free media, and placed 
into 24-well plates containing serum-free media, or CM. 
For inhibitors, SB505124 [2 μM], ruxolitinib [100 nM] or 
DMSO [0.05%] were added to the inserts and wells. After 
16 h, cells were fixed in methanol and stained. The total 
number of cells that migrated was counted.
Luciferase assays
ECs (25,000) were seeded in 24-well culture 
plates. After 24 h, ECs were transfected with a STAT3 
luciferase reporter (Promega), and Renilla to control 
for transfection efficiency, using Lipofectamine 2000. 
After overnight serum starvation, media was replaced 
with control media or CM for 24 h, and luciferase assays 
were performed on three independent experiments as 
described [32].
3-dimensional culture
KRC and SVEC4–10 cells were cultured in 3D 
as described [32]. Briefly, KRC PCCs were transduced 
with an eGFP lentiviral construct (Clontech), and 
SVEC4–10 ECs were labeled using the PKH26 red 
fluorescent cell linker kit per the manufacturer’s 
recommendations (Sigma-Aldrich). 3,000 PCCs 
or 6,000 ECs were cultured alone or together in 
3% matrigel. Two days after plating, and every 
two days thereafter, cells were treated with control 
media, or media with ruxolitinib [100 nM]. The final 
concentration of DMSO in all experiments was 0.05%. 
Images were acquired with a Leica DMI3000 inverted 
microscope outfitted with a DFC300 FX camera. 
Fluorescence intensity was determined on three 
independent experiments plated in duplicate using 
Image Pro Plus v.7 (Media Cybernetics).
Immunoblotting
ECs (200,000/well) were seeded in 6-well plates, 
serum-starved, and media was replaced with control 
or conditioned media containing SB505124 [2 μM], 
ruxolitinib [100 nM] or DMSO [0.05%]. Lysates 
were prepared and immunoblotting was performed as 
described [32]. For STAT3 knockdown, lysates were 
prepared from control- and shRNA-transduced cells 48h 
post-seeding.
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Statistical analysis  
One-way ANOVA with Tukey’s post-hoc test, one-
tailed Student’s t-test, or log rank Kaplan-Meier survival 
analysis was used to test for significant differences using 
Sigma Plot v.11.0 software (Systat Software). All statistics 
were performed on triplicate experiments. A P < .05 was 
considered statistically significant, and asterisks denote 
significant differences.
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